ID   RON_HUMAN               Reviewed;        1400 AA.
AC   Q04912; A0A087WZG2; B5A944; B5A945; B5A946; B5A947;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 3.
DT   12-OCT-2022, entry version 220.
DE   RecName: Full=Macrophage-stimulating protein receptor;
DE            Short=MSP receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=CDw136;
DE   AltName: Full=Protein-tyrosine kinase 8;
DE   AltName: Full=p185-Ron;
DE   AltName: CD_antigen=CD136;
DE   Contains:
DE     RecName: Full=Macrophage-stimulating protein receptor alpha chain;
DE   Contains:
DE     RecName: Full=Macrophage-stimulating protein receptor beta chain;
DE   Flags: Precursor;
GN   Name=MST1R; Synonyms=PTK8, RON;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RON), AND VARIANTS GLN-322 AND ARG-523.
RC   TISSUE=Keratinocyte;
RX   PubMed=8386824;
RA   Ronsin C., Muscatelli F., Mattei M.-G., Breathnach R.;
RT   "A novel putative receptor protein tyrosine kinase of the met family.";
RL   Oncogene 8:1195-1202(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RX   PubMed=8816464; DOI=10.1128/mcb.16.10.5518;
RA   Collesi C., Santoro M.M., Gaudino G., Comoglio P.M.;
RT   "A splicing variant of the RON transcript induces constitutive tyrosine
RT   kinase activity and an invasive phenotype.";
RL   Mol. Cell. Biol. 16:5518-5526(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS RON-1; RON-2; RON-3 AND RON-4).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   INTERACTION WITH PIK3R1.
RX   PubMed=7687741; DOI=10.1128/mcb.13.8.4600-4608.1993;
RA   Ponzetto C., Bardelli A., Maina F., Longati P., Panayotou G., Dhand R.,
RA   Waterfield M.D., Comoglio P.M.;
RT   "A novel recognition motif for phosphatidylinositol 3-kinase binding
RT   mediates its association with the hepatocyte growth factor/scatter factor
RT   receptor.";
RL   Mol. Cell. Biol. 13:4600-4608(1993).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=8062829; DOI=10.1002/j.1460-2075.1994.tb06659.x;
RA   Gaudino G., Follenzi A., Naldini L., Collesi C., Santoro M., Gallo K.A.,
RA   Godowski P.J., Comoglio P.M.;
RT   "RON is a heterodimeric tyrosine kinase receptor activated by the HGF
RT   homologue MSP.";
RL   EMBO J. 13:3524-3532(1994).
RN   [7]
RP   FUNCTION.
RX   PubMed=7939629; DOI=10.1126/science.7939629;
RA   Wang M.-H., Ronsin C., Gesnel M.-C., Coupey L., Skeel A., Leonard E.J.,
RA   Breatnach R.;
RT   "Identification of the ron gene product as the receptor for the human
RT   macrophage stimulating protein.";
RL   Science 266:117-119(1994).
RN   [8]
RP   FUNCTION IN WOUND HEALING RESPONSE.
RX   PubMed=9764835; DOI=10.1046/j.1523-1747.1998.00332.x;
RA   Nanney L.B., Skeel A., Luan J., Polis S., Richmond A., Wang M.H.,
RA   Leonard E.J.;
RT   "Proteolytic cleavage and activation of pro-macrophage-stimulating protein
RT   and upregulation of its receptor in tissue injury.";
RL   J. Invest. Dermatol. 111:573-581(1998).
RN   [9]
RP   INTERACTION WITH ITGB1.
RX   PubMed=10222149; DOI=10.1006/excr.1999.4429;
RA   Danilkovitch A., Skeel A., Leonard E.J.;
RT   "Macrophage stimulating protein-induced epithelial cell adhesion is
RT   mediated by a PI3-K-dependent, but FAK-independent mechanism.";
RL   Exp. Cell Res. 248:575-582(1999).
RN   [10]
RP   INTERACTION WITH MST1.
RX   PubMed=10514476; DOI=10.1074/jbc.274.42.29937;
RA   Danilkovitch A., Miller M., Leonard E.J.;
RT   "Interaction of macrophage-stimulating protein with its receptor. Residues
RT   critical for beta chain binding and evidence for independent alpha chain
RT   binding.";
RL   J. Biol. Chem. 274:29937-29943(1999).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=12472665; DOI=10.1046/j.1365-3083.2002.01177.x;
RA   Wang M.H., Zhou Y.Q., Chen Y.Q.;
RT   "Macrophage-stimulating protein and RON receptor tyrosine kinase: potential
RT   regulators of macrophage inflammatory activities.";
RL   Scand. J. Immunol. 56:545-553(2002).
RN   [12]
RP   UBIQUITINATION.
RX   PubMed=12802274; DOI=10.1038/sj.onc.1206585;
RA   Penengo L., Rubin C., Yarden Y., Gaudino G.;
RT   "c-Cbl is a critical modulator of the Ron tyrosine kinase receptor.";
RL   Oncogene 22:3669-3679(2003).
RN   [13]
RP   INTERACTION WITH HYAL2.
RX   PubMed=12676986; DOI=10.1073/pnas.0837136100;
RA   Danilkovitch-Miagkova A., Duh F.-M., Kuzmin I., Angeloni D., Liu S.-L.,
RA   Miller A.D., Lerman M.I.;
RT   "Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and
RT   mediates transformation of epithelial cells by jaagsiekte sheep
RT   retrovirus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4580-4585(2003).
RN   [14]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=15184888; DOI=10.1038/sj.onc.1207650;
RA   Conrotto P., Corso S., Gamberini S., Comoglio P.M., Giordano S.;
RT   "Interplay between scatter factor receptors and B plexins controls invasive
RT   growth.";
RL   Oncogene 23:5131-5137(2004).
RN   [15]
RP   PHOSPHORYLATION AT TYR-1238; TYR-1239; TYR-1353 AND TYR-1360, AND ACTIVITY
RP   REGULATION.
RX   PubMed=15632155; DOI=10.1074/jbc.m412623200;
RA   Yokoyama N., Ischenko I., Hayman M.J., Miller W.T.;
RT   "The C terminus of RON tyrosine kinase plays an autoinhibitory role.";
RL   J. Biol. Chem. 280:8893-8900(2005).
RN   [16]
RP   FUNCTION.
RX   PubMed=18836480; DOI=10.1038/onc.2008.383;
RA   Feres K.J., Ischenko I., Hayman M.J.;
RT   "The RON receptor tyrosine kinase promotes MSP-independent cell spreading
RT   and survival in breast epithelial cells.";
RL   Oncogene 28:279-288(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   INTERACTION WITH GAB1 AND GRB2.
RX   PubMed=21784853; DOI=10.1074/jbc.m111.239384;
RA   Chaudhuri A., Xie M.H., Yang B., Mahapatra K., Liu J., Marsters S.,
RA   Bodepudi S., Ashkenazi A.;
RT   "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal
RT   transduction by the related receptor tyrosine kinases RON and MET.";
RL   J. Biol. Chem. 286:32762-32774(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.24 ANGSTROMS) OF 1060-1357 IN COMPLEX WITH AMP-PNP
RP   AND MAGNESIUM, ACTIVE SITE, AND PHOSPHORYLATION AT TYR-1238.
RX   PubMed=20726546; DOI=10.1021/bi100409w;
RA   Wang J., Steinbacher S., Augustin M., Schreiner P., Epstein D.,
RA   Mulvihill M.J., Crew A.P.;
RT   "The crystal structure of a constitutively active mutant RON kinase
RT   suggests an intramolecular autophosphorylation hypothesis.";
RL   Biochemistry 49:7972-7974(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 42-568, GLYCOSYLATION AT ASN-488,
RP   AND DISULFIDE BONDS.
RX   PubMed=22848655; DOI=10.1371/journal.pone.0041912;
RA   Chao K.L., Tsai I.W., Chen C., Herzberg O.;
RT   "Crystal structure of the Sema-PSI extracellular domain of human RON
RT   receptor tyrosine kinase.";
RL   PLoS ONE 7:E41912-E41912(2012).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-75; THR-95; CYS-185; GLN-322; ASP-356;
RP   LEU-434; ASP-465; CYS-504; ARG-523; PRO-613; MET-900; GLY-1304; GLY-1335
RP   AND CYS-1360.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [22]
RP   VARIANTS NPCA3 HIS-306; THR-327; GLY-670 AND THR-973, AND INVOLVEMENT IN
RP   NPCA3.
RX   PubMed=26951679; DOI=10.1073/pnas.1523436113;
RA   Dai W., Zheng H., Cheung A.K., Tang C.S., Ko J.M., Wong B.W., Leong M.M.,
RA   Sham P.C., Cheung F., Kwong D.L., Ngan R.K., Ng W.T., Yau C.C., Pan J.,
RA   Peng X., Tung S., Zhang Z., Ji M., Chiang A.K., Lee A.W., Lee V.H.,
RA   Lam K.O., Au K.H., Cheng H.C., Yiu H.H., Lung M.L.;
RT   "Whole-exome sequencing identifies MST1R as a genetic susceptibility gene
RT   in nasopharyngeal carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:3317-3322(2016).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the
CC       extracellular matrix into the cytoplasm by binding to MST1 ligand.
CC       Regulates many physiological processes including cell survival,
CC       migration and differentiation. Ligand binding at the cell surface
CC       induces autophosphorylation of RON on its intracellular domain that
CC       provides docking sites for downstream signaling molecules. Following
CC       activation by ligand, interacts with the PI3-kinase subunit PIK3R1,
CC       PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by
CC       RON leads to the activation of several signaling cascades including the
CC       RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the
CC       wound healing response by promoting epithelial cell migration,
CC       proliferation as well as survival at the wound site. Also plays a role
CC       in the innate immune response by regulating the migration and
CC       phagocytic activity of macrophages. Alternatively, RON can also promote
CC       signals such as cell migration and proliferation in response to growth
CC       factors other than MST1 ligand. {ECO:0000269|PubMed:18836480,
CC       ECO:0000269|PubMed:7939629, ECO:0000269|PubMed:9764835}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- ACTIVITY REGULATION: In its inactive state, the C-terminal tail
CC       interacts with the catalytic domain and inhibits the kinase activity.
CC       Upon ligand binding, the C-terminal tail is displaced and becomes
CC       phosphorylated, thus increasing the kinase activity.
CC       {ECO:0000269|PubMed:15632155}.
CC   -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain which are
CC       disulfide linked. Binds PLXNB1. Associates with and is negatively
CC       regulated by HYAL2. Interacts when phosphorylated with downstream
CC       effectors including PIK3R1, PCLG1, GRB2 and GAB1. Interacts with
CC       integrin beta1/ITGB1 in a ligand-independent fashion.
CC       {ECO:0000269|PubMed:10222149, ECO:0000269|PubMed:10514476,
CC       ECO:0000269|PubMed:12676986, ECO:0000269|PubMed:15184888,
CC       ECO:0000269|PubMed:20726546, ECO:0000269|PubMed:21784853,
CC       ECO:0000269|PubMed:7687741}.
CC   -!- INTERACTION:
CC       Q04912; P26927: MST1; NbExp=5; IntAct=EBI-2637518, EBI-6929133;
CC       Q04912; O43157: PLXNB1; NbExp=3; IntAct=EBI-2637518, EBI-1111488;
CC       Q04912; O15031: PLXNB2; NbExp=2; IntAct=EBI-2637518, EBI-722004;
CC       Q04912; Q9ULL4: PLXNB3; NbExp=2; IntAct=EBI-2637518, EBI-311073;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=RON;
CC         IsoId=Q04912-1; Sequence=Displayed;
CC       Name=Delta-RON; Synonyms=sf-RON;
CC         IsoId=Q04912-2; Sequence=VSP_005007;
CC       Name=RON-1;
CC         IsoId=Q04912-3; Sequence=VSP_038920, VSP_038921;
CC       Name=RON-2;
CC         IsoId=Q04912-4; Sequence=VSP_038919, VSP_038922, VSP_038923;
CC       Name=RON-3;
CC         IsoId=Q04912-5; Sequence=VSP_038924, VSP_038925;
CC       Name=RON-4;
CC         IsoId=Q04912-6; Sequence=VSP_038922, VSP_038923;
CC       Name=RON-5;
CC         IsoId=Q04912-7; Sequence=VSP_038919;
CC   -!- TISSUE SPECIFICITY: Expressed in colon, skin, lung and bone marrow.
CC       {ECO:0000269|PubMed:8062829}.
CC   -!- PTM: Proteolytic processing yields the two subunits.
CC   -!- PTM: Autophosphorylated in response to ligand binding on Tyr-1238 and
CC       Tyr-1239 in the kinase domain leading to further phosphorylation of
CC       Tyr-1353 and Tyr-1360 in the C-terminal multifunctional docking site.
CC       {ECO:0000269|PubMed:15632155, ECO:0000269|PubMed:20726546}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor
CC       stability and activity through proteasomal degradation.
CC       {ECO:0000269|PubMed:12802274}.
CC   -!- DISEASE: Nasopharyngeal carcinoma, 3 (NPCA3) [MIM:617075]: A form of
CC       nasopharyngeal carcinoma, a malignant neoplasm that originates in the
CC       nasopharyngeal epithelium and includes 4 subtypes: keratinizing
CC       squamous cell, non-keratinizing, basaloid squamous cell, and papillary
CC       adenocarcinoma. {ECO:0000269|PubMed:26951679}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform Delta-RON]: Lacks part of the extracellular
CC       domain, oligomerizes and is constitutively activated. Expressed at
CC       higher level in cancer cells. {ECO:0000303|PubMed:26951679}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RONID287.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X70040; CAA49634.1; -; mRNA.
DR   EMBL; EU826582; ACF47618.1; -; mRNA.
DR   EMBL; EU826583; ACF47619.1; -; mRNA.
DR   EMBL; EU826584; ACF47620.1; -; mRNA.
DR   EMBL; EU826585; ACF47621.1; -; mRNA.
DR   EMBL; AC105935; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KC876868; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2807.1; -. [Q04912-1]
DR   CCDS; CCDS58833.1; -. [Q04912-2]
DR   CCDS; CCDS82777.1; -. [Q04912-7]
DR   PIR; I38185; I38185.
DR   RefSeq; NP_001231866.1; NM_001244937.2. [Q04912-2]
DR   RefSeq; NP_002438.2; NM_002447.3. [Q04912-1]
DR   PDB; 3PLS; X-ray; 2.24 A; A=1060-1357.
DR   PDB; 4FWW; X-ray; 1.85 A; A=42-568.
DR   PDB; 4QT8; X-ray; 3.00 A; A/B=25-683.
DR   PDBsum; 3PLS; -.
DR   PDBsum; 4FWW; -.
DR   PDBsum; 4QT8; -.
DR   AlphaFoldDB; Q04912; -.
DR   SMR; Q04912; -.
DR   BioGRID; 110592; 99.
DR   DIP; DIP-6029N; -.
DR   IntAct; Q04912; 144.
DR   MINT; Q04912; -.
DR   STRING; 9606.ENSP00000296474; -.
DR   BindingDB; Q04912; -.
DR   ChEMBL; CHEMBL2689; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q04912; -.
DR   GuidetoPHARMACOLOGY; 1816; -.
DR   GlyGen; Q04912; 8 sites.
DR   iPTMnet; Q04912; -.
DR   PhosphoSitePlus; Q04912; -.
DR   BioMuta; MST1R; -.
DR   DMDM; 294862462; -.
DR   EPD; Q04912; -.
DR   jPOST; Q04912; -.
DR   MassIVE; Q04912; -.
DR   MaxQB; Q04912; -.
DR   PaxDb; Q04912; -.
DR   PeptideAtlas; Q04912; -.
DR   PRIDE; Q04912; -.
DR   ProteomicsDB; 58294; -. [Q04912-1]
DR   ProteomicsDB; 58295; -. [Q04912-2]
DR   ProteomicsDB; 58296; -. [Q04912-3]
DR   ProteomicsDB; 58297; -. [Q04912-4]
DR   ProteomicsDB; 58298; -. [Q04912-5]
DR   ProteomicsDB; 58299; -. [Q04912-6]
DR   ABCD; Q04912; 13 sequenced antibodies.
DR   Antibodypedia; 2092; 995 antibodies from 38 providers.
DR   DNASU; 4486; -.
DR   Ensembl; ENST00000296474.8; ENSP00000296474.3; ENSG00000164078.14. [Q04912-1]
DR   Ensembl; ENST00000344206.8; ENSP00000341325.4; ENSG00000164078.14. [Q04912-2]
DR   Ensembl; ENST00000621387.4; ENSP00000482642.1; ENSG00000164078.14. [Q04912-7]
DR   GeneID; 4486; -.
DR   KEGG; hsa:4486; -.
DR   MANE-Select; ENST00000296474.8; ENSP00000296474.3; NM_002447.4; NP_002438.2.
DR   UCSC; uc003cxy.5; human. [Q04912-1]
DR   CTD; 4486; -.
DR   DisGeNET; 4486; -.
DR   GeneCards; MST1R; -.
DR   HGNC; HGNC:7381; MST1R.
DR   HPA; ENSG00000164078; Tissue enhanced (skin, stomach).
DR   MalaCards; MST1R; -.
DR   MIM; 600168; gene.
DR   MIM; 617075; phenotype.
DR   neXtProt; NX_Q04912; -.
DR   OpenTargets; ENSG00000164078; -.
DR   PharmGKB; PA31186; -.
DR   VEuPathDB; HostDB:ENSG00000164078; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG3610; Eukaryota.
DR   GeneTree; ENSGT00940000157842; -.
DR   HOGENOM; CLU_005158_0_0_1; -.
DR   InParanoid; Q04912; -.
DR   OrthoDB; 408584at2759; -.
DR   PhylomeDB; Q04912; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q04912; -.
DR   Reactome; R-HSA-8852405; Signaling by MST1.
DR   SignaLink; Q04912; -.
DR   SIGNOR; Q04912; -.
DR   BioGRID-ORCS; 4486; 6 hits in 1106 CRISPR screens.
DR   ChiTaRS; MST1R; human.
DR   GeneWiki; MST1R; -.
DR   GenomeRNAi; 4486; -.
DR   Pharos; Q04912; Tchem.
DR   PRO; PR:Q04912; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q04912; protein.
DR   Bgee; ENSG00000164078; Expressed in mucosa of transverse colon and 114 other tissues.
DR   ExpressionAtlas; Q04912; baseline and differential.
DR   Genevisible; Q04912; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0001725; C:stress fiber; IEA:Ensembl.
DR   GO; GO:0005773; C:vacuole; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0006909; P:phagocytosis; IBA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007338; P:single fertilization; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd11279; Sema_RON; 1.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016201; PSI.
DR   InterPro; IPR039413; RON_Sema.
DR   InterPro; IPR001627; Semap_dom.
DR   InterPro; IPR036352; Semap_dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016244; Tyr_kinase_HGF/MSP_rcpt.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF01403; Sema; 1.
DR   Pfam; PF01833; TIG; 2.
DR   PIRSF; PIRSF000617; TyrPK_HGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00429; IPT; 3.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00630; Sema; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF101912; SSF101912; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF81296; SSF81296; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS51004; SEMA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Cleavage on pair of basic residues; Disease variant; Disulfide bond;
KW   Glycoprotein; Immunity; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..1400
FT                   /note="Macrophage-stimulating protein receptor"
FT                   /id="PRO_0000024452"
FT   CHAIN           25..304
FT                   /note="Macrophage-stimulating protein receptor alpha chain"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000024453"
FT   CHAIN           310..1400
FT                   /note="Macrophage-stimulating protein receptor beta chain"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000024454"
FT   TOPO_DOM        25..957
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        958..978
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        979..1400
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          31..522
FT                   /note="Sema"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352"
FT   DOMAIN          569..671
FT                   /note="IPT/TIG 1"
FT   DOMAIN          684..767
FT                   /note="IPT/TIG 2"
FT   DOMAIN          770..860
FT                   /note="IPT/TIG 3"
FT   DOMAIN          1082..1345
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1367..1400
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1208
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:20726546"
FT   BINDING         1088..1096
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         1114
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         1161..1164
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         1212
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         1238
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:15632155,
FT                   ECO:0000305|PubMed:20726546"
FT   MOD_RES         1239
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:15632155"
FT   MOD_RES         1353
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15632155"
FT   MOD_RES         1360
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15632155"
FT   CARBOHYD        66
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        419
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        458
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        488
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22848655"
FT   CARBOHYD        654
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        720
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        841
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        897
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        101..104
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        107..162
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        135..143
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        174..177
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        300..367
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        385..407
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        386..422
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        527..545
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        533..567
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        536..552
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   DISULFID        548..558
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352,
FT                   ECO:0000269|PubMed:22848655"
FT   VAR_SEQ         411..516
FT                   /note="Missing (in isoform RON-2 and isoform RON-5)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038919"
FT   VAR_SEQ         475..495
FT                   /note="ELVRSLNYLLYVSNFSLGDSG -> GPHPHSPLALGPCLHPHFAHI (in
FT                   isoform RON-1)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038920"
FT   VAR_SEQ         496..1400
FT                   /note="Missing (in isoform RON-1)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038921"
FT   VAR_SEQ         628..647
FT                   /note="PVPRKDFVEEFECELEPLGT -> YNLVPPLPFPEGGNQAAPSP (in
FT                   isoform RON-2 and isoform RON-4)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038922"
FT   VAR_SEQ         648..1400
FT                   /note="Missing (in isoform RON-2 and isoform RON-4)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038923"
FT   VAR_SEQ         884..932
FT                   /note="Missing (in isoform Delta-RON)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005007"
FT   VAR_SEQ         884..907
FT                   /note="YIGLGAVADCVGINVTVGGESCQH -> VSVRDRGRDSWGSESRGQPTGWSS
FT                   (in isoform RON-3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038924"
FT   VAR_SEQ         908..1400
FT                   /note="Missing (in isoform RON-3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_038925"
FT   VARIANT         75
FT                   /note="R -> S (in dbSNP:rs35887539)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041768"
FT   VARIANT         95
FT                   /note="P -> T (in dbSNP:rs55908300)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041769"
FT   VARIANT         185
FT                   /note="R -> C (in dbSNP:rs55633379)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041770"
FT   VARIANT         306
FT                   /note="R -> H (in NPCA3; dbSNP:rs200046052)"
FT                   /evidence="ECO:0000269|PubMed:26951679"
FT                   /id="VAR_076928"
FT   VARIANT         322
FT                   /note="R -> Q (in dbSNP:rs2230593)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8386824"
FT                   /id="VAR_006350"
FT   VARIANT         327
FT                   /note="A -> T (in NPCA3; unknown pathological significance;
FT                   dbSNP:rs200757776)"
FT                   /evidence="ECO:0000269|PubMed:26951679"
FT                   /id="VAR_076929"
FT   VARIANT         356
FT                   /note="G -> D (in dbSNP:rs35924402)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041771"
FT   VARIANT         434
FT                   /note="S -> L (in dbSNP:rs2230591)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_029238"
FT   VARIANT         440
FT                   /note="N -> S (in dbSNP:rs2230592)"
FT                   /id="VAR_029239"
FT   VARIANT         465
FT                   /note="G -> D (in dbSNP:rs34564898)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041772"
FT   VARIANT         504
FT                   /note="R -> C (in dbSNP:rs34350470)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041773"
FT   VARIANT         523
FT                   /note="Q -> R (in dbSNP:rs2230590)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8386824"
FT                   /id="VAR_041774"
FT   VARIANT         613
FT                   /note="Q -> P (in dbSNP:rs35986685)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041775"
FT   VARIANT         670
FT                   /note="V -> G (in NPCA3; unknown pathological significance;
FT                   dbSNP:rs201024956)"
FT                   /evidence="ECO:0000269|PubMed:26951679"
FT                   /id="VAR_076930"
FT   VARIANT         900
FT                   /note="V -> M (in dbSNP:rs56091918)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041776"
FT   VARIANT         973
FT                   /note="A -> T (in NPCA3; unknown pathological significance;
FT                   dbSNP:rs773053723)"
FT                   /evidence="ECO:0000269|PubMed:26951679"
FT                   /id="VAR_076931"
FT   VARIANT         1195
FT                   /note="G -> S (in dbSNP:rs7433231)"
FT                   /id="VAR_061749"
FT   VARIANT         1304
FT                   /note="R -> G (in dbSNP:rs528985327)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041777"
FT   VARIANT         1335
FT                   /note="R -> G (in dbSNP:rs1062633)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_024577"
FT   VARIANT         1360
FT                   /note="Y -> C (in dbSNP:rs56330223)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041778"
FT   CONFLICT        209
FT                   /note="A -> G (in Ref. 1; CAA49634)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        813
FT                   /note="R -> RQ (in Ref. 3; ACF47620)"
FT                   /evidence="ECO:0000305"
FT   STRAND          43..45
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          48..50
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          55..62
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          64..66
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          68..74
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          77..81
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          87..92
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          96..98
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   HELIX           102..105
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          120..126
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   TURN            127..130
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          131..138
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          143..151
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          154..157
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   TURN            166..168
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          184..191
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          194..201
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           205..208
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          215..221
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          233..235
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           239..242
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          248..255
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          258..268
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          269..271
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          275..288
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           290..292
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          294..302
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          316..318
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          320..328
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           331..337
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          344..351
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          365..370
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           371..386
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          387..389
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   TURN            399..401
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          407..409
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   HELIX           422..424
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          433..436
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   TURN            438..445
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          448..456
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          459..466
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          469..475
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          485..491
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          503..505
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          508..513
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          516..521
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           527..529
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           533..538
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           541..543
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          549..553
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   HELIX           555..557
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   TURN            559..561
FT                   /evidence="ECO:0007829|PDB:4FWW"
FT   STRAND          563..567
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          570..575
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          578..580
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          589..593
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          609..615
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          639..641
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          653..659
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   STRAND          672..682
FT                   /evidence="ECO:0007829|PDB:4QT8"
FT   HELIX           1064..1069
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1071..1073
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1077..1079
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1080..1091
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1094..1102
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1104..1106
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1108..1116
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1122..1136
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1148..1150
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1153..1155
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1158..1161
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1169..1174
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1182..1201
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1211..1213
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1214..1216
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   STRAND          1222..1224
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   TURN            1232..1235
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1236..1239
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1250..1253
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1256..1259
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1266..1282
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   TURN            1287..1290
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1293..1295
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1296..1301
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1314..1323
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1328..1330
FT                   /evidence="ECO:0007829|PDB:3PLS"
FT   HELIX           1334..1347
FT                   /evidence="ECO:0007829|PDB:3PLS"
SQ   SEQUENCE   1400 AA;  152241 MW;  358672D466B8E70D CRC64;
     MELLPPLPQS FLLLLLLPAK PAAGEDWQCP RTPYAASRDF DVKYVVPSFS AGGLVQAMVT
     YEGDRNESAV FVAIRNRLHV LGPDLKSVQS LATGPAGDPG CQTCAACGPG PHGPPGDTDT
     KVLVLDPALP ALVSCGSSLQ GRCFLHDLEP QGTAVHLAAP ACLFSAHHNR PDDCPDCVAS
     PLGTRVTVVE QGQASYFYVA SSLDAAVAAS FSPRSVSIRR LKADASGFAP GFVALSVLPK
     HLVSYSIEYV HSFHTGAFVY FLTVQPASVT DDPSALHTRL ARLSATEPEL GDYRELVLDC
     RFAPKRRRRG APEGGQPYPV LRVAHSAPVG AQLATELSIA EGQEVLFGVF VTGKDGGPGV
     GPNSVVCAFP IDLLDTLIDE GVERCCESPV HPGLRRGLDF FQSPSFCPNP PGLEALSPNT
     SCRHFPLLVS SSFSRVDLFN GLLGPVQVTA LYVTRLDNVT VAHMGTMDGR ILQVELVRSL
     NYLLYVSNFS LGDSGQPVQR DVSRLGDHLL FASGDQVFQV PIQGPGCRHF LTCGRCLRAW
     HFMGCGWCGN MCGQQKECPG SWQQDHCPPK LTEFHPHSGP LRGSTRLTLC GSNFYLHPSG
     LVPEGTHQVT VGQSPCRPLP KDSSKLRPVP RKDFVEEFEC ELEPLGTQAV GPTNVSLTVT
     NMPPGKHFRV DGTSVLRGFS FMEPVLIAVQ PLFGPRAGGT CLTLEGQSLS VGTSRAVLVN
     GTECLLARVS EGQLLCATPP GATVASVPLS LQVGGAQVPG SWTFQYREDP VVLSISPNCG
     YINSHITICG QHLTSAWHLV LSFHDGLRAV ESRCERQLPE QQLCRLPEYV VRDPQGWVAG
     NLSARGDGAA GFTLPGFRFL PPPHPPSANL VPLKPEEHAI KFEYIGLGAV ADCVGINVTV
     GGESCQHEFR GDMVVCPLPP SLQLGQDGAP LQVCVDGECH ILGRVVRPGP DGVPQSTLLG
     ILLPLLLLVA ALATALVFSY WWRRKQLVLP PNLNDLASLD QTAGATPLPI LYSGSDYRSG
     LALPAIDGLD STTCVHGASF SDSEDESCVP LLRKESIQLR DLDSALLAEV KDVLIPHERV
     VTHSDRVIGK GHFGVVYHGE YIDQAQNRIQ CAIKSLSRIT EMQQVEAFLR EGLLMRGLNH
     PNVLALIGIM LPPEGLPHVL LPYMCHGDLL QFIRSPQRNP TVKDLISFGL QVARGMEYLA
     EQKFVHRDLA ARNCMLDESF TVKVADFGLA RDILDREYYS VQQHRHARLP VKWMALESLQ
     TYRFTTKSDV WSFGVLLWEL LTRGAPPYRH IDPFDLTHFL AQGRRLPQPE YCPDSLYQVM
     QQCWEADPAV RPTFRVLVGE VEQIVSALLG DHYVQLPATY MNLGPSTSHE MNVRPEQPQF
     SPMPGNVRRP RPLSEPPRPT
//
